ERBB2 and breast neoplasm: This study represented a preliminary exploration of dalpiciclib in NET, and provides evidence suggesting that the combination of dalpiciclib and AI exhibits a comparable safety profile and therapeutic response to NCT in patients with HR+ HER2 negative breast tumors.